The development of novel immunotherapeutic approaches in multiple myeloma

Leukemia and Lymphoma

Volumn 49, Issue 4, 2008, Pages 652-654

  Peinert, Stefan ^a   Prince, H Miles ^a   Harrison, Simon ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; T LYMPHOCYTE ANTIGEN; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; APOPTOSIS; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CELL INTERACTION; CELL LYSATE; CELL PROLIFERATION; DENDRITIC CELL; DISEASE COURSE; DISEASE MODEL; DOWN REGULATION; HUMAN; IMMUNOGENICITY; INNATE IMMUNITY; LYMPHOCYTE TRANSFUSION; MULTIPLE MYELOMA; NONHUMAN; NOTE; PLASMA CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTES;

EID: 42049097961     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802007742     Document Type: Note

References (23)

1. Harrison, S. J., Cook, S. J., Nibbs, G. and Prince, H. M. (2006) Immunotherapy of multiple myeloma: The start of a long and tortuous journey. Expert Rev Anticancer Ther, 6, pp. 1769-1785.
2. Bollard, C. M. (2003) Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative disease. Acta Haematol, 110, pp. 139-148.
3. Dudley, M. E. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, pp. 2346-2357.
4. Small, E. J. (2006) Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol, 24, pp. 3089-3094.
5. Gratwohl, A. (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet, 352, pp. 1087-1092.
6. van Rhee, F. (1998) et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant, 21, pp. 1055-1061.
7. Hsu, F. J. (1997) Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood, 89, pp. 3129-3135.
8. van Rhee, F., Szmania, F., Zhan, S. M., Gupta, F., Pomtree, S. K. and Lin, M. (2005) NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood
9. Barratt-Boyes, S. M. (1996) Making the most of mucin: A novel target for tumor immunotherapy. Cancer Immunol Immunother, 43, pp. 142-151.
10. Timmerman, J. M. (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Blood, 99, pp. 1517-1526.
11. Azuma, T. (2004) Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res, 10, pp. 7402-7412.
12. Frank, C., Hundemer, M., Ho, A. D., Goldschmidt, H. and Witzens-Harig, M. (2008) Cellular immune responses against the cancer testis antigen SPAN-XB in healthy donors and patients with multiple myeloma. Leuk Lymphoma, 49, pp. 7787-7784.
13. Morgan, R. A. (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314, pp. 126-129.
14. Park, J. R., Digiusto, D. L., Slovak, M., Wright, C., Naranjo, A. and Wagner, J. (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther, 15, pp. 825-833.
15. Klebanoff, C. A. (2005) Sinks, suppressors and antigen presenters: How lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol, 26, pp. 111-117.
16. Schumacher, T NM (1991) Peptide selection by MHC class I molecules. 350, pp. 703-706.
17. Haynes, N. M. (2002) Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood, 100, pp. 3155-3163.
18. Westwood, J. A. (2005) Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci USA, 102, pp. 19051-19056.
19. Hönemann, D., Guru, P., Westwood, J. A., Kershaw, M. H., Smyth, M. J. and Trapani, J. A. (2007) Targeting Lewis Y positive Multiple Myeloma with gene-modified T cells.
20. Ritchie, D. S. (2007) Plasma cell lysate as an antigen source in multiple myeloma immunotherapy. Leuk Lymphoma, 48, pp. 1894-1895.
21. Elrick, L. J. (2005) Punish the parent not the progeny. Blood, 105, pp. 1862-1866.
22. Matsui, W. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, pp. 2332-2336.
23. Matsui, W. (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res, 68, pp. 190-197.